The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Global Federation of International Societies of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN)
J Pediatr Gastroenterol Nutr. 2020 Mar 20.
doi: 10.1097/MPG.0000000000002710.Online ahead of print.
Giuseppe Indolfi 1, Björn Fischler 2, Regino P Gonzalez-Peralta 3, Mirta Ciocca 4, Gilda Porta 5, Mohan Neelam 6, Mohammed El-Guindi 7, Deirdre Kelly 8, Yen-Hsuan Ni 9, Anupan Sibal 10, Daniel H Leung 11, Mei Hwei Chang 12, Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN)
Author information
1Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze, Italy.
2Department of Paediatrics, Karolinska University Hospital, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
3Pediatric GI, Hepatology and Liver Transplant, AdventHealth for Children and Transplant Institute, Atlanta, US.
4Pediatric Hepatology and Liver Transplant Section of German Hospital, Buenos Aires, Argentina.
5Unidade de Hepatologia Instituto da Criança HC-FMUSP, São Paulo, Brasil.
6Department of Pediatric Gastroenterology,Hepatology & Liver Transplantation, Medanta - The Medicity Hospital, Gurgaon (Haryana), India.
7National Liver Institute, Menofiya University, Egypt.
8Birmingham Women's and Children's Hospital and University of Birmingham, Birmingham, UK.
9Department of Pediatrics, College of Medicine, National Taiwan University, Taipei, Taiwan.
10Indraprastha Apollo Hospitals, New Delhi, India.
11Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, US.
12Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
Objective:This position paper written by the Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition aimed to systematically evaluate clinical practice guidelines (CPGs), medical consensus and position papers on the use of direct-acting antivirals (DAA) to treat chronic hepatitis C virus (HCV) infection in adolescents and children in order to compare recommendations and provide the basis for developing a unified position statement.
Methods:MEDLINE, Cochrane-Library, National Guideline Clearinghouse and select websites of relevant societies/organizations were used to identify CPGs, medical consensus and position papers between 2011-2019.
Results:A total of five documents were analysed: three CPGs, one medical consensus and one position paper. All publications were consistent in recommending DAA treatment for adolescents (12-17 years-old) with chronic HCV infection. Similarly, all of these publications consistently recommended deferring therapy for children between 3 and 11 years of age until DAA became available as standard of care. Finally, none of the included publications recommended treating children younger than 3 years old. By contrast, there was significant discrepancy across the retrieved documents regarding specific DAA regimens and treatment strategies.
Conclusions:There is strong consensus on treating all adolescents with chronic HCV infection with DAA and on delaying therapy in younger children until these agents are approved for them. Interferon-based therapies should be avoided. Specific recommendations regarding which DAA regimen to use and treatment duration varied significantly. Key stakeholders need to convene to standardize therapeutic strategies at a global level if we are to eradicate HCV in children.